Coming Off Hormone Therapy: tapering and when to stop

There is no single right time to stop hormone therapy. The decision usually weighs symptom burden, time since menopause, cardiovascular and breast risk, and personal goals. Tapering may blunt symptom rebound for some, though evidence is mixed, and symptoms can return at any point after discontinuation.

Most conversations about hormone therapy focus on starting it. The harder conversation — and often the more personal one — is when to stop. There is no universal expiration date on menopausal hormone therapy (MHT), and the research does not point to a single right answer. What it does offer is a framework: weigh current symptom burden, time since menopause, personal risk profile, and what you actually want the next decade to look like.

This is a guide to that decision, not a prescription for it.

Is there a "right" time to stop HRT?

The honest answer is no.

For years, patients were told to stop hormone therapy at five years, or at age 60, or at some other round number. The 2022 position statement from The Menopause Society (NAMS) explicitly moves away from that framing. For healthy women under 60 or within 10 years of menopause onset, the benefit-risk profile of systemic hormone therapy is generally favorable when the indication is bothersome vasomotor symptoms, sleep disruption, or genitourinary symptoms, or for prevention of bone loss in appropriate candidates.

As women move further from menopause onset or past age 60, the balance shifts. Cardiovascular risk, breast cancer risk, and venous thromboembolism risk evolve. That does not mean therapy must stop at 60 — it means the conversation about continuing should be revisited more carefully each year.

What actually changes when you stop

In plain English: your body loses the exogenous estrogen signal.

Within days to weeks, circulating estradiol falls to post-menopausal baseline. For some women, that transition is unremarkable. For others, vasomotor symptoms — hot flashes, night sweats, sleep fragmentation — return, sometimes at intensity comparable to the original menopausal transition.

Data from the Women's Health Initiative follow-up showed that after stopping conjugated equine estrogens plus medroxyprogesterone acetate, roughly half of women who had been on therapy for symptom control experienced symptom return, and a meaningful minority described those symptoms as moderate to severe. Grady and colleagues, in a secondary analysis of HERS, found that women who had moderate-to-severe vasomotor symptoms at the time of discontinuation were substantially more likely to have difficulty stopping.

Other shifts to expect:

• Bone turnover accelerates. Bone mineral density gains made on therapy can erode within one to two years of stopping, which matters more for women with baseline osteopenia or fracture risk factors.
• Genitourinary symptoms often return — vaginal dryness, dyspareunia, urinary urgency — and these are the symptoms most likely to persist indefinitely without local treatment.
• Sleep and mood can shift again, particularly if sleep quality was a major reason therapy helped in the first place.

Taper or stop cold turkey?

What the evidence actually says.

This is where patients expect a clean answer and the literature does not provide one. Lindh-Åstrand and colleagues ran a randomized trial comparing abrupt discontinuation to a taper over several weeks in women who had been treated for vasomotor symptoms. At one year, the proportion of women with returned symptoms and the proportion who restarted therapy were similar between groups. The taper did not reliably prevent symptom return — it may have delayed it.

That said, many clinicians still favor a gradual reduction, for two practical reasons:

1. A taper lets you distinguish between a transient withdrawal flare and a true, sustained return of symptoms that would warrant restarting. 2. A slower reduction gives time to layer in non-hormonal strategies (SSRIs/SNRIs, cognitive behavioral therapy for insomnia, gabapentin, fezolinetant) before symptoms fully re-emerge.

A typical taper might involve reducing the estrogen dose stepwise over two to three months, or extending the dosing interval for transdermal preparations. The specifics depend on the formulation, the indication, and the clinician.

The core takeawayThere is no universal stop date for hormone therapy — the decision is a yearly recalculation of symptoms, risks, and goals, and tapering may soften the landing without preventing symptom return.

How to decide if now is the time

Tuned to your numbers, not a calendar.

A useful annual check-in, done with a clinician who knows your history, usually covers:

• Current symptom burden on therapy. If you no longer have hot flashes or sleep disruption, you may be treating a problem that has resolved on its own. The menopausal transition is finite; vasomotor symptoms persist a median of 7 to 10 years, but not forever for most.
• Reason you started. Vasomotor symptoms, bone protection, genitourinary syndrome of menopause, and premature ovarian insufficiency each have different trajectories and different stopping calculus.
• Evolving risk profile. New cardiovascular diagnoses, breast findings, VTE events, or migraine with aura change the equation.
• Age and time since menopause. Past age 60 or 10 years post-menopause, continuing systemic therapy benefits from a more explicit risk conversation, per NAMS and ACOG.
• Non-hormonal options you have not tried. For vasomotor symptoms specifically, there are now approved non-hormonal medications that did not exist a decade ago.

The best time to stop is usually when the reason you started no longer applies — and the honest way to find that out is to try.

What if symptoms come back hard?

Restarting is a legitimate option. Nothing about stopping is irreversible, and a trial off therapy that produces intolerable symptoms is diagnostic information, not failure. The 2022 NAMS statement is explicit that duration of use should be individualized and that there is no arbitrary cap for women who continue to derive benefit and remain appropriate candidates.

For genitourinary symptoms alone, low-dose vaginal estrogen is a separate conversation from systemic therapy. Its systemic absorption is minimal, its safety profile differs, and many women who stop systemic therapy continue vaginal estrogen indefinitely.

The practical path forward

If you are considering coming off hormone therapy, the useful work happens before the taper starts:

• Document your current symptoms honestly (a two-week symptom log beats memory).
• Review the original indication and whether it still applies.
• If you choose to do bloodwork, the markers worth having in front of a clinician include a lipid panel, fasting glucose or A1c, and — depending on history — a DEXA scan to anchor the bone conversation.
• Decide in advance what you will do if symptoms return, so the decision is not made at 3 a.m. in a damp t-shirt.

Coming off hormone therapy is a clinical decision with a personal center of gravity. The science can tell you what tends to happen; it cannot tell you what you want the next phase to feel like. That part is yours.

References

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. Source
2. Haskell SG, et al. The effect of discontinuing postmenopausal hormone therapy on the risk of fracture, breast cancer, and other outcomes: findings from the Women's Health Initiative. Arch Intern Med. 2008. Source
3. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol. 2003;102(6):1233-1239. Source
4. Lindh-Åstrand L, Bixo M, Hirschberg AL, Sundström-Poromaa I, Hammar M. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause. 2010;17(1):72-79. Source
5. ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407-1410. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.